Trial · NCT06096181
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Total Opioid Consumption (IV and PO in MME) on POD# 0 and 1 | Propofol + Remifentanil | MME POD 0 | 36.30 | Inter-Quartile Range 71.90 | MME |
| Total Opioid Consumption (IV and PO in MME) on POD# 0 and 1 | Propofol + Dexmedetomidine | MME POD 0 | 70.5 | Inter-Quartile Range 66.98 | MME |
| Total Opioid Consumption (IV and PO in MME) on POD# 0 and 1 | Propofol + Remifentanil | MME POD 1 | 57.5 | Inter-Quartile Range 32.5 to 61.7 | MME |
| Total Opioid Consumption (IV and PO in MME) on POD# 0 and 1 | Propofol + Dexmedetomidine | MME POD 1 | 48 | Inter-Quartile Range 41.9 to 54.1 | MME |
| Mean VAS Pain Score on POD# 0 and 1 | Propofol + Remifentanil | VAS POD 0 | 3.39 | Standard Deviation 2.30 | Visual Analog Pain Scale Score |
| Mean VAS Pain Score on POD# 0 and 1 | Propofol + Dexmedetomidine | VAS POD 0 | 2.23 | Standard Deviation 1.40 | Visual Analog Pain Scale Score |
| Mean VAS Pain Score on POD# 0 and 1 | Propofol + Remifentanil | VAS POD 1 | 3.32 | Standard Deviation 2.81 | Visual Analog Pain Scale Score |
| Mean VAS Pain Score on POD# 0 and 1 | Propofol + Dexmedetomidine | VAS POD 1 | 3.21 | Standard Deviation 0.98 | Visual Analog Pain Scale Score |
| Time From Skin Closure to Participant Being Able to Move Their Feet on Command (Mins) | Propofol + Remifentanil | 14 | Inter-Quartile Range 9 to 18 | Minutes | |
| Time From Skin Closure to Participant Being Able to Move Their Feet on Command (Mins) | Propofol + Dexmedetomidine | 21.5 | Inter-Quartile Range 10 to 30.75 | Minutes | |
| Time From Skin Closure to Extubation | Propofol + Remifentanil | 15 | Inter-Quartile Range 9.5 to 19 | Minutes | |
| Time From Skin Closure to Extubation | Propofol + Dexmedetomidine | 22 | Inter-Quartile Range 11.75 to 31.75 | Minutes | |
| Total Opioid Consumption (IV and PO in MME) on POD# 0 and 1 | Propofol + Remifentanil | MME POD 0 | 75.12 | Standard Deviation 71.58 | MME |
| Total Opioid Consumption (IV and PO in MME) on POD# 0 and 1 | Propofol + Dexmedetomidine | MME POD 0 | 88.93 | Standard Deviation 66.98 | MME |
| Total Opioid Consumption (IV and PO in MME) on POD# 0 and 1 | Propofol + Remifentanil | MME POD 1 | 54.38 | Standard Deviation 28.12 | MME |
| Total Opioid Consumption (IV and PO in MME) on POD# 0 and 1 | Propofol + Dexmedetomidine | MME POD 1 | 52.20 | Standard Deviation 27.40 | MME |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06096181/results